Trial Profile
Open-label, Single Arm, Multi-centre, Phase II Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin With Superficial and Interstitial Laser Light Application in Patients With Recurrent Head and Neck Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Fimaporfin (Primary) ; Bleomycin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Acronyms ENHANCE
- Sponsors PCI Biotech
- 08 Jun 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 22 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 22 Dec 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.